Suven’s Alzheimer’s drug Masupirdine clears key safety review, Phase 3 stays on track
The DSMB approved the ongoing Phase 3 trial of Masupirdine after a safety review of half the participants, finding no concerns and recommending no changes. Enrollment has reached 88% and is on schedule for September 2026 completion, with top‑line results expected in Q2 2027, bolstering Suven’s CNS pipeline.